A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. METHODS: In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. RESULTS: Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. CONCLUSIONS: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systemic administration of recombinant IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [141]
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Self-citationinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Gajewski, T. F., & Fitch, F. W. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4245 · Cited by 834
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
Research works printed but not linked: 1
- Okada T, 1993, Lymphokine Cytokine Res, 12, 87
Cited by
Items 201–300 of 649
del Castillo, A. G., Simeón‐Aznar, C. P., Fonollosa‐Pla, V., Alonso-Vila, S., Reverté-Vinaixa, M. M., Muñoz, X., Pallisa, E., Selva-O’Callaghan, A., Fernández‐Codina, A., & Vilardell, M. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.07.002 · Cited by 58
Interferon-γ1b Therapy in Idiopathic Pulmonary Fibrosis
Bajwa, E. K., Ayas, N., Schulzer, M., Mak, E., Ryu, J. H., & Malhotra, A. (2005) · CHEST Journal · doi:10.1378/chest.128.1.203 · Cited by 60
Xu, Y., Wang, L., Butticè, G., Sengupta, P. K., & Smith, B. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404174200 · Cited by 58
D’Alessandro‐Gabazza, C. N., Kobayashi, T., Boveda-Ruiz, D., Takagi, T., Toda, M., Gil-Bernabe, P., Miyake, Y., Yasukawa, A., Matsuda, Y., 昇, 鈴., et al. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0158oc · Cited by 59
Enhanced protection from fibrosis and inflammation in the combined absence of IL‐13 and IFN‐γ
Ramalingam, T. R., Gieseck, R. L., Acciani, T. H., M Hart, K., Cheever, A. W., Mentink‐Kane, M. M., Vannella, K. M., & Wynn, T. A. (2016) · The Journal of Pathology · doi:10.1002/path.4733 · Cited by 55
“cytokine responses [39–42], with IFN-γ suppressing myofibroblast function and IL-4 and IL-13 augmenting their activity [16,43].”
BackgroundPirfenidone: significant treatment effects in idiopathic pulmonary fibrosis
Hilberg, O., Simonsen, U., du Bois, R. M., & Bendstrup, E. M. (2012) · The Clinical Respiratory Journal · doi:10.1111/j.1752-699x.2012.00302.x · Cited by 56
“During the last decade, several novel treatments for IPF including bosentan (endothelin receptor antagonist) (29), imatinib (tyrosine kinase inhibitor) (30), etanercept [tumor necrosis factor (TNF)-a inhibitor] (31), interferron-g-1b (32) and anticoagulation (warfarin) (33) have been evaluated in randomized clinical t…”
BackgroundOverexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis
Kimura, T., Ishii, Y., Yoh, K., Morishima, Y., Iizuka, T., Kiwamoto, T., Matsuno, Y., Homma, S., Nomura, A., Sakamoto, T., et al. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.051160 · Cited by 55
Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface
Valatas, V., Filidou, E., Drygiannakis, I., & Kolios, G. (2017) · Annals of Gastroenterology · doi:10.20524/aog.2017.0146 · Cited by 69
Jo, H. E., Troy, L. K., Keir, G. J., Chambers, D. C., Holland, A. E., Goh, N. S. L., WILSHER, M. L., de Boer, S., Moodley, Y. P., Grainge, C., et al. (2017) · Respirology · doi:10.1111/resp.13146 · Cited by 61
Cellular and Molecular Mechanisms of Intestinal Fibrosis
Wu, X., Lin, X., Tan, J., Liu, Z., He, J., Hu, F., Wang, Y., Chen, M., Liu, F., & Mao, R. (2023) · Gut and Liver · doi:10.5009/gnl220045 · Cited by 57
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
Antoniou, K. M., Margaritopoulos, G. A., & Siafakas, N. M. (2013) · European Respiratory Review · doi:10.1183/09059180.00002113 · Cited by 53
Escape from the Matrix: Multiple Mechanisms for Fibroblast Activation in Pulmonary Fibrosis
Laurent, G. J., McAnulty, R. J., Hill, M., & Chambers, R. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200710-159dr · Cited by 54
“This was given impetus by the reports in a small group of patients that IFN-g was an effective treatment for IPF (24), although this early promise was not borne out in a recent large multicenter trial ( 25 ).”
Gui, X., Qiu, X., Tian, Y., Xie, M., Li, H., Gao, Y., Zhuang, Y., Cao, M., Ding, H. J., Ding, J., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.02.039 · Cited by 52
Autoimmunity and interstitial lung disease
Jindal, S. K., & Agarwal, R. (2005) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000170522.71497.61 · Cited by 51
Otaki, N., Motomura, Y., Terooatea, T. W., Kelly, S. T., Mochizuki, M., Takeno, N., Koyasu, S., Tamamitsu, M., Sugihara, F., Kikuta, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43336-6 · Cited by 52
Idiopathic Pulmonary Fibrosis: New Concepts in Pathogenesis and Implications for Drug Therapy
Horowitz, J. C., & Thannickal, V. J. (2006) · Treatments in Respiratory Medicine · doi:10.2165/00151829-200605050-00004 · Cited by 52
“[189] In this large phase III trial, no significant benefit was seen in general use in the treatment of IPF.”
Nitric oxide, hypoxia, and superoxide: the good, the bad, and the ugly!
Dweik, R. A. (2005) · Thorax · doi:10.1136/thx.2004.038471 · Cited by 57
Quantification of Inflammatory Markers in Laryngotracheal Stenosis
Motz, K., Yin, L. X., Samad, I., Ding, D., Murphy, M. K., Duvvuri, M., & Hillel, A. T. (2017) · Otolaryngology · doi:10.1177/0194599817706930 · Cited by 50
Advances in Aerosols: Adult Respiratory Disease
Smaldone, G. C. (2006) · Journal of Aerosol Medicine · doi:10.1089/jam.2006.19.36 · Cited by 49
Increased epithelial permeability in pulmonary fibrosis in relation to disease progression
Goh, N. S. L., Desai, S. R., Anagnostopoulos, C., Hansell, D. M., Hoyles, R. K., Sato, H., Denton, C. P., Black, C. M., du Bois, R. M., & Wells, A. U. (2010) · European Respiratory Journal · doi:10.1183/09031936.00010910 · Cited by 50
The role of chemokines and cytokines in lung fibrosis
Keane, M. P. (2008) · European Respiratory Review · doi:10.1183/09059180.00010908 · Cited by 48
Pirfenidone for the treatment of idiopathic pulmonary fibrosis
Antoniu, S. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.823 · Cited by 51
Clinical review: Idiopathic pulmonary fibrosis—Past, present and future
Dempsey, O. J. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2006.08.017 · Cited by 60
Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice
Ou, X., Feng, Y., Wen, F., Huang, X., Xiao, J., Wang, K., & Wang, T. (2008) · Chinese Medical Journal · doi:10.1097/00029330-200809020-00013 · Cited by 50
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis
Luppi, F., Cerri, S., Beghé, B., Fabbri, L. M., & Richeldi, L. (2004) · Respiratory Medicine · doi:10.1016/j.rmed.2004.07.019 · Cited by 49
Pathology of interstitial lung disease
Leslie, K. O. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.05.002 · Cited by 48
Toll-like Receptors, Notch Ligands, and Cytokines Drive the Chronicity of Lung Inflammation
Raymond, T., Schaller, M. A., Hogaboam, C. M., Lukacs, N. W., Rochford, R. A., & Kunkel, S. L. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200706-067th · Cited by 49
Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines
Чучалин, А. Г., Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Демура, Т. А., Ilkovich, M. M., Коган, Е. А., Samsonova, M. V., Speranskaya, A. A., Tyurin, I. E., et al. (2016) · PULMONOLOGIYA · doi:10.18093/0869-0189-2016-26-4-399-419 · Cited by 49
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Raghu, G. (2017) · European Respiratory Review · doi:10.1183/16000617.0071-2017 · Cited by 45
Self-citationIdiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy
Thannickal, V. J., Flaherty, K. R., Martínez, F. J., & Lynch, J. P. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.8.1671 · Cited by 45
Dyspnea in interstitial lung disease
Collard, H. R., & Pantilat, S. Z. (2008) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3282ff6336 · Cited by 47
Raghu, G., King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Leconte, I., Roux, S., & Swigris, J. (2010) · European Respiratory Journal · doi:10.1183/09031936.00188108 · Cited by 43
Self-citationThe Pulmonary Side of Reflux Disease: from Heartburn to Lung Fibrosis
Allaix, M. E., Fisichella, P. M., Noth, I., Mendez, B. M., & Patti, M. G. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-013-2208-3 · Cited by 44
Tachibana, K., Inoue, Y., Nishiyama, A., Sugimoto, C., Matsumuro, A., Hirose, M., Kitaichi, M., Akira, M., Arai, T., Hayashi, S., et al. (2011) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 43
Effective nebulization of interferon-γ using a novel vibrating mesh
Sweeney, L., McCloskey, A. P., Higgins, G., Ramsey, J. M., Cryan, S., & MacLoughlin, R. J. (2019) · Respiratory Research · doi:10.1186/s12931-019-1030-1 · Cited by 43
“A multinational study of 330 IPF patients showing the subcutaneous administration of IFN-γ versus placebo, concluded that IFN-γ did not affect progression-free survival, pulmonary function, or the quality of life [8].”
BackgroundEvolving Perspectives on Innate Immune Mechanisms of IPF
Ishikawa, G., Liu, A., & Herzog, E. L. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.676569 · Cited by 47
“Additionally, despite early promise, administration of recombinant interferon gamma was also abandoned due to lack of efficacy (Raghu et al., 2004).”
BackgroundGrowth Factors and Cytokines in Acute Lung Injury
Deng, J. C., & Standiford, T. J. (2010) · Comprehensive physiology · doi:10.1002/cphy.c090011 · Cited by 48
Patient-Reported Outcomes in Idiopathic Pulmonary Fibrosis Research
Swigris, J. J., & Fairclough, D. L. (2012) · CHEST Journal · doi:10.1378/chest.11-2602 · Cited by 46
Leppäranta, O., Tikkanen, J., Bespalov, M. M., Koli, K. M., & Myllärniemi, M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0201oc · Cited by 46
Mishra, A., Bhattacharya, P., Paul, S., Paul, R., & Swarnakar, S. (2011) · Lung India · doi:10.4103/0970-2113.83972 · Cited by 43
“Several trials with different agents like colchicin,[3,4] INF-γ,[5-7] antioxidants,[8,9] pirfenidone,[10,11] and”
BackgroundQuality of life and health status in interstitial lung diseases
Vries, J. D., & Drent, M. (2006) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000239553.93443.d8 · Cited by 41
Chang, C., Lin, C., Lee, C., Chuang, H., Shih, F.-C., Wan, S.-W., Tai, C., & Chen, C. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114356 · Cited by 46
Survival in idiopathic pulmonary fibrosis—cytotoxic agents compared to corticosteroids
Pereira, C. A. C., Malheiros, T., Coletta, E. M., Ferreira, R. G., Rubin, A. S., Otta, J. S., & Rocha, N. S. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.05.008 · Cited by 45
Gläser, S., Obst, A., Koch, B., Henkel, B., Grieger, A., Felix, S. B., Halank, M., Bruch, L., Bollmann, T., Warnke, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065643 · Cited by 40
“The data shown by du Bois base on patients evaluated within interventional trials, and it remains unclear whether these trials include substantial numbers of patients with interacting PH [32,33].”
BackgroundPulmonary hypertension in interstitial lung disease
Polomis, D. A., Runo, J. R., & Meyer, K. C. (2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283043e30 · Cited by 41
Tzortzaki, E. G., Antoniou, K. M., Zervou, M. I., Lambiri, I., Koutsopoulos, A. V., Tzanakis, Ν., Plataki, M. E., Maltezakis, G., Bouros, D. E., & Siafakas, N. M. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.02.006 · Cited by 45
Nicholson, A. G. (2008) · Springer eBooks · doi:10.1007/978-0-387-68792-6_19 · Cited by 41
Emmez, H., Kardeş, Ö., Doğulu, F. H., Kurt, G., Memış, L., & Baykaner, M. K. (2008) · Neurosurgery · doi:10.1227/01.neu.0000317272.86593.e3 · Cited by 39
Current diagnosis and management of idiopathic pulmonary fibrosis: A survey of academic physicians
Collard, H. R., Loyd, J. E., King, T. E., & LANCASTER, L. H. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.03.012 · Cited by 42
“[15-21] Third, the increasingly accepted pathophysiologic paradigm of abnormal wound healing in which inflammation plays a limited role argues against the traditional approach to therapy (corticosteroids and cytotoxic agents) proposed by the consensus statement.”
BackgroundSelf-citationBeneficial effects of bile acid receptor agonists in pulmonary disease models
Comeglio, P., Morelli, A., Adorini, L., Maggi, M., & Vignozzi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1385760 · Cited by 43
“tive results obtained in two randomized studies [136,137].”
Hagaman, J. T., Kinder, B. W., & Eckman, M. H. (2010) · Lung · doi:10.1007/s00408-009-9217-8 · Cited by 39
Antifibrosis: To Reverse the Irreversible
Paz, Z., & Shoenfeld, Y. (2009) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-009-8157-7 · Cited by 43
Update on diagnosis and treatment of idiopathic pulmonary fibrosis
Martínez, J. A. B., Baldi, B. G., da Costa, C. H., Jezler, S. F. D. O., Lima, M. S., & Rufino, R. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000000152 · Cited by 43
“(17) The aforementioned findings led to two multicenter, randomized, double-blind, placebo-controlled studies, the results of which were disappointing.(18,19) Those two studies were important because they showed that large, placebo-controlled clinical trials were feasible in patients with IPF, marking the beginning of…”
BackgroundMoon, S. W., Kim, S. Y., Chung, M. P., Yoo, H., Jeong, S. H., Kim, D. S., Song, J. W., Lee, H. L., Choi, S. M., Kim, Y. W., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202005-451oc · Cited by 40
The Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Behr, J. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0875 · Cited by 44
Biologic Treatments in Interstitial Lung Diseases
Karampitsakos, Τ., Vraka, A., Bouros, D. E., Liossis, S. C., & Τzouvelekis, Α. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00041 · Cited by 38
Fiorucci, E., Lucantoni, G., Paone, G., Zotti, M., Li, B. E., Serpilli, M., Regimenti, P., Cammarella, I., Puglisi, G., & Schmid, G. (2008) · PubMed · Cited by 43
Lynch, J. P., Fishbein, M. C., Saggar, R., Zisman, D. A., & Belperio, J. A. (2007) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.1.3.377 · Cited by 37
Wang, J., Lesko, M. B., Badri, M. H., Kapoor, B. C., Wu, B. G., Li, Y., Smaldone, G. C., Bonneau, R., Kurtz, Z. D., Condos, R., et al. (2017) · ERJ Open Research · doi:10.1183/23120541.00008-2017 · Cited by 41
Th1/Th2 Immune Response in Lung Fibroblasts in Interstitial Lung Disease
Sumida, A., Hasegawa, Y., Okamoto, M., Hashimoto, N., Imaizumi, K., Yatsuya, H., Yokoi, T., Takagi, K., Shimokata, K., & Kawabe, T. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2008.02.005 · Cited by 38
Verma, G., Marras, T. K., Chowdhury, N., & Singer, L. G. (2011) · Canadian Respiratory Journal · doi:10.1155/2011/109635 · Cited by 41
“Recent clinical trials for IPF have included some evaluation of HRQL, although no therapies have shown a positive impact on HRQL (1-5).”
BackgroundMethodInnate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis
Strieter, R. M., & Keane, M. P. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22398 · Cited by 39
“was evidence for a significant survival advantage in patients treated with IFN-γ (15).”
BackgroundMethodInfluentialTreatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
Sköld, C. M., Bendstrup, E. M., Myllärniemi, M., Guðmundsson, G., Sjåheim, T., Hilberg, O., Altraja, A., Kaarteenaho, R. L., & Ferrara, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12571 · Cited by 38
“‘Triple therapy’ and N-acetylcysteine monotherapy Triple therapy of prednisone, azathioprine and Nacetylcysteine (NAC) was previously the standard Study (year) Ref Duration (weeks) n Intervention Primary outcome variable Result Raghu et al. (2004) [67] 58 330 IFN-c Disease progression NEG Azuma et al. (2005) [88] 63 1…”
Harari, S. A., & Caminati, A. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00719.x · Cited by 37
“A large multicenter, randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferonc-1b has been recently completed (122).”
BackgroundClinical use of biomarkers of survival in pulmonary fibrosis
Thomeer, M., Grutters, J. C., Wuyts, W. A., Willems, S., & Demedts, M. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-89 · Cited by 38
“analysed retrospectively data from the placebo group (168 IPF patients with mild to moderate disease) of a trial evaluating interferon gamma as treatment for IPF [6,34].”
MethodIdiopathic Pulmonary Fibrosis: New Insights to Functional Characteristics at Diagnosis
Cortés-Telles, A., Forkert, L., O’Donnell, D. E., & Moran‐Mendoza, O. (2014) · Canadian Respiratory Journal · doi:10.1155/2014/825606 · Cited by 35
“The mean FVC in our study (71%) was similar to several studies that have reported FVC in patients with IPF (6,8,10,14,15) but higher than the FVC reported by others (2,9,11,16).”
BackgroundResultEvidence-based treatment strategies in idiopathic pulmonary fibrosis
Behr, J. (2013) · European Respiratory Review · doi:10.1183/09059180.00001013 · Cited by 40
Type I interferon therapy and its role in autoimmunity
Biggioggero, M., Gabbriellini, L., & Meroni, P. L. (2010) · Autoimmunity · doi:10.3109/08916930903510971 · Cited by 34
“IFNa Small cell lung carcinoma [4] Actinic keratoses [5] Behcet’s disease [6] Mycosis fungoides [7] Discoid lupus erythematosus [8] Haemangiomas [9] Hairy cell leukaemia [10] Multiple myeloma [11] Hodgkin’s lymphoma [12] Non-Hodgkin’s lymphoma [13] IFNb Remitting-relapsing multiple sclerosis [14] IFNg Hepatitis B and…”
BackgroundNathan, S. D., Mehta, J., Stauffer, J. L., Morgenthien, E. A., Yang, M., Limb, S. L., & Bhorade, S. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071427 · Cited by 33
“Patients with IPF from two independent Phase III, double-blind, placebo-controlled trials of IFN-γ-1b (GIPF-001 (NCT00047645) and GIPF-007 (NCT00075998)) were analyzed and used as a validation cohort [14,15].”
MethodResultEffect of Feining on bleomycin-induced pulmonary injuries in rats
Liang, X., Tian, Q., Wei, Z., Liu, F., Chen, J., Zhao, Y., Qü, P., Huang, X., Zhou, X., Liu, N., et al. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.02.008 · Cited by 35
AAV6-Mediated IL-10 Expression in the Lung Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice
Kurosaki, F., Uchibori, R., Sehara, Y., Saga, Y., Urabe, M., Mizukami, H., Hagiwara, K., & Kume, A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.024 · Cited by 34
Stem cell-based therapy for fibrotic diseases: mechanisms and pathways
Taherian, M., Bayati, P., & Mojtabavi, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03782-5 · Cited by 39
“Although, Corticosteroids, anti-inflammatory agents, and immune-suppressive drugs, are used experimentally to treat IPF for many years, have no beneficial effects on survival or disease progression [188–190], and occasionally worsen disease outcomes during clinical IPF trials [191].”
BackgroundZolak, J. S., & de Andrade, J. A. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.08.006 · Cited by 38
IPF: New insight in diagnosis and prognosis
Caminati, A., & Harari, S. A. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.03.012 · Cited by 37
Collard, H. R., Brown, K. K., Martínez, F. J., Raghu, G., Roberts, R., & Anstrom, K. J. (2014) · CHEST Journal · doi:10.1378/chest.14-0492 · Cited by 35
Self-citationPharmacological treatment of idiopathic pulmonary fibrosis: an update
Spagnolo, P., Wells, A. U., & Collard, H. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.001 · Cited by 33
Nathan, S. D., Yang, M., Morgenthien, E. A., & Stauffer, J. L. (2020) · European Respiratory Journal · doi:10.1183/13993003.02151-2019 · Cited by 31
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease
Gibson, C. D., Kugler, M. C., Deshwal, H., Munger, J. S., & Condos, R. (2020) · Lung · doi:10.1007/s00408-020-00370-1 · Cited by 32
Advanced Lung Disease: Quality of Life and Role of Palliative Care
Gilbert, C. R., & Smith, C. M. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20091 · Cited by 32
Clinical Predictors of Survival in Idiopathic Pulmonary Fibrosis
Kim, J. H., Lee, J. H., Ryu, Y. J., & Chang, J. H. (2012) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2012.73.3.162 · Cited by 33
Shoda, H., Yokoyama, A., Nishino, R., Nakashima, T., Ishikawa, N., Haruta, Y., Hattori, N., Naka, T., & Kohno, N. (2007) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2006.12.128 · Cited by 34
Idiopathic pulmonary fibrosis: current trends in management
Raghu, G., & Chang, J. A. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.08.002 · Cited by 32
Self-citationCaminati, A., Madotto, F., Conti, S., Cesana, G., Mantovani, L. G., & Harari, S. A. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02651-w · Cited by 32
Review: New perspectives in the treatment of idiopathic pulmonary fibrosis
Rogliani, P., Mura, M., Porretta, M. A., & Saltini, C. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808089363 · Cited by 34
“…carried out by Ziesche et al. [1999], however, the trial was deemed to show that there was a benefit in survival and disease progression among patients with less advanced fibrosis, suggesting that a clinically significant longer term survival benefit could not be ruled out [Raghu et al. 2004].”
Inhibitory effects of Hu-qi-yin on the bleomycin-induced pulmonary fibrosis in rats
Zhou, X., Zhang, G.-C., Li, J., & Hou, J. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.11.029 · Cited by 30
Idiopathic pulmonary fibrosis mortality: update on trends in the modern treatment era
Podolanczuk, A. J., & Raghu, G. (2024) · European Respiratory Journal · doi:10.1183/13993003.01305-2024 · Cited by 31
Self-citationInterferon-γ Treatment of Human Laryngotracheal Stenosis–Derived Fibroblasts
Motz, K., Samad, I., Yin, L. X., Murphy, M. K., Duvvuri, M., Ding, D., & Hillel, A. T. (2017) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2017.0977 · Cited by 29
Pirfenidone treatment of idiopathic pulmonary fibrosis
Gomer, R. H., Gan, & Herzog, E. L. (2011) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s12209 · Cited by 33
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program
Richeldi, L., & du Bois, R. M. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.52 · Cited by 29
Xia, Y., Xia, Y., Lv, Q., Yue, M., Qiao, S., Yang, Y., Wei, Z., & Dai, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13421 · Cited by 30
“IFN-γ-1b can improve the dyspnea symptoms of patients with idiopathic PF (Raghu et al., 2004; Bouros et al., 2006); HGF suppresses the fibrotic changes in the lung tissues of PF mice, and a small molecule mimetic of HGF has been used to treat patients with refractory PF (Yaekashiwa et al.”
BackgroundMethodPharmacologic therapies for idiopathic pulmonary fibrosis, past and future
Staitieh, B. S., Renzoni, E. A., & Veeraraghavan, S. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.991751 · Cited by 32
“Initial clinical trials showed a trend toward decreased mortality (24) but the INSPIRE study, a larger prospective trial, failed to show any survival benefit with subcutaneous IFN-γ treatment (11).”
BackgroundPlantier, L., Renaud, H., Respaud, R., Marchand-Adam, S., & Crestani, B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122091 · Cited by 30
Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis
Sari, E., He, C., & Margaroli, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911443 · Cited by 29
“The failure of the PANTHER trial, together with two failed randomized Phase III trials evaluating interferon gamma-1β [19,20], marked a significant shift in developing therapies for IPF.”
MethodInterferon-γ1bfor the treatment of idiopathic pulmonary fibrosis
Bouros, D. E., Antoniou, K. M., Τzouvelekis, Α., & Siafakas, N. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1051 · Cited by 30
Herpesviruses: a cofactor in the pathogenesis of idiopathic pulmonary fibrosis?
Doran, P., & Egan, J. J. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00235.2005 · Cited by 28
Progression of native lung fibrosis in lung transplant recipients with idiopathic pulmonary fibrosis
Elicker, B. M., Golden, J. A., Ordovas, K. G., Leard, L. E., Golden, T. R., & Hays, S. R. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.10.019 · Cited by 28
Exercise training in idiopathic pulmonary fibrosis
Vainshelboim, B., Fox, B. D., de Oliveira, J. J. F., & Kramer, M. R. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1121104 · Cited by 30
Vaccinia vaccine–based immunotherapy arrests and reverses established pulmonary fibrosis
Collins, S. L., Chan‐Li, Y., Oh, M. H., Vigeland, C. L., Limjunyawong, N., Mitzner, W., Powell, J. D., & Horton, M. R. (2016) · JCI Insight · doi:10.1172/jci.insight.83116 · Cited by 28
Promising pharmacologic innovations in treating pulmonary fibrosis
Bhatt, N., Baran, C., ALLEN, J., MAGRO, C. M. J., & Marsh, C. B. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.003 · Cited by 29
Metadata
- Authors
- Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E.
- Affiliations
- University of Washington (US)
- National Jewish Health (US)
- Yale University (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-08
- Volume
- 350
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108226118
- Cited by
- 652
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 15 · 2021: 16 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 22 · 2016: 21 · 2015: 29 · 2014: 20 · 2013: 38 · 2012: 39
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, interferon gamma-1b, progression-free survival, corticosteroid-refractory disease, lung function, quality of life, mortality, pneumonia, constitutional symptoms, medication adherence
- MeSH terms
- Double-Blind Method, Female, Humans, Injections, Subcutaneous, Interferon-gamma, Male, Middle Aged, Pulmonary Fibrosis, Recombinant Proteins, Respiratory Function Tests, Respiratory Tract Infections, Risk, Proportional Hazards Models, Treatment Failure, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.